New Compounds Protect Nervous System From the Structural Damage Characteristic of Multiple Sclerosis
Pharmacological Agents Hold Promise for Several Neurodegenerative Disorders
A newly characterized group of pharmacological compounds block both the inflammation and nerve cell damage seen in mouse models of multiple sclerosis, according to a study conducted at the Icahn School of Medicine at Mount Sinai and published online this week in the journal Nature Neuroscience.
Multiple sclerosis is a disease of the brain and spinal cord, where for unknown reasons, the body’s immune system begins an inflammatory attack against myelin, the protective nerve coating that surrounds nerve fibers. Once myelin is stripped from these fibers, the nerve cells become highly susceptible to damage, which is believed to underlie their destruction, leading to the steady clinical decline seen in progressive forms of multiple sclerosis.
“The compounds identified in this study, when administered orally, both reduced the inflammation that is a hallmark of multiple sclerosis and protected against the nerve cell damage seen in mouse models of the disease,” said Jeffery Haines, PhD, a post-doctoral fellow at Mount Sinai and the study's lead author. “The multiple sclerosis drugs currently on the market and being tested elsewhere seek to reduce the immune attack on cells, but none target neurodegeneration nor do they work to restore nerve cell function. The findings of this new study represent an exciting step in the process of advancing new oral treatment options.”
Previous research conducted at Mount Sinai found that the trafficking of protein molecules between the nucleus (the cellular compartment containing the genetic information of the cell) and the cytoplasm is altered in neurodegenerative disease. The molecule that shuttles proteins between the nucleus and cytoplasm, XPO1 (also called CRM1,) has been implicated in multiple sclerosis and a number of other diseases.
Specifically, the Mount Sinai study was designed to test whether pharmacological compounds designed to block the function of XPO1/CRM1 could stop disease progression in mouse models that exhibit some of the characteristics of MS. Researchers found that two chemical agents (called KPT-276 and KPT-350) prevented XPO1/CRM1 from shuttling cargo out of the nucleus of nerve cells, which protected them from free radicals and structural damage. The compounds also stopped inflammatory cells from multiplying, thereby reducing inflammation.
Mice showing hindlimb paralysis were able to regain motor function within two weeks after KPT-276 or KPT-350 were orally administered.
“The study results elucidate the molecular mechanisms underlying disease progression in multiple sclerosis models, providing a basis for future clinical trials to determine safety and efficacy of these chemical agents in humans with demyelinating disorders,” says Patrizia Casaccia, MD, PhD, Professor of Neuroscience, Genetics and Genomic Sciences at Mount Sinai and senior author of the study.
Because traffic of molecules between the nucleus and the cytoplasm of nerve cells is altered in several other neurodegenerative disorders, targeting nuclear transport may have broader therapeutic implications in diseases like amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease.
The study was conducted in collaboration with Karyopharm Therapeutics, Inc. and supported by the National Institute for Neurological Disorders and Stroke at the National Institutes of Health and by funds from the National Multiple Sclerosis initiative Fast-Forward. Dr. Jeffery Haines was supported by postdoctoral fellowships from the Multiple Sclerosis Society of Canada and Fonds de recherche du Québec – Santé.
Study co-authors include: Olivier Herbin, PhD, Belén de la Hera, Oscar G Vidaurre, MD, PhD, Gregory A Moy, and Konstantina Alexandropoulos, PhD from the Icahn School of Medicine; Qingxiang Sun, Ho Yee Joyce Fung and Yuh Min Chook, PhD from the University of Texas Southwestern Medical Center; Stephanie Albrecht and Tanja Kuhlmann, MD from the University Hospital Münster, Germany; Dilara McCauley, PhD and Sharon Shacham, PhD from Karyopharm Therapeutics; and Grahame Kidd, PhD from the Cleveland Clinic.
About the Mount Sinai Health System
Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with 48,000 employees working across eight hospitals, more than 400 outpatient practices, more than 600 research and clinical labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time—discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.
Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 9,000 primary and specialty care physicians and 11 free-standing joint-venture centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida. Hospitals within the System are consistently ranked by Newsweek’s® “The World’s Best Smart Hospitals, Best in State Hospitals, World Best Hospitals and Best Specialty Hospitals” and by U.S. News & World Report's® “Best Hospitals” and “Best Children’s Hospitals.” The Mount Sinai Hospital is on the U.S. News & World Report® “Best Hospitals” Honor Roll for 2024-2025.
For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.